The Company’s ambition is to transform patient outcomes in cancer, especially those where there are limited options, and the cancer often reoccurs with resistance, such as the platinum resistant or refractory ovarian cancer.

TILT’s CEO and founder, Akseli Hemminki, has pioneered individualized use of oncolytic immunotherapy, treating almost 300 patients with ten different types of oncolytic viruses.

The Company has several ongoing clinical studies in Europe and the USA. To find out more information on the trials please go to:

TILT Biotherapeutics trial entries in

Patient Resources

TILT-123 can be administered by intravenous, intratumoral, intraperitoneal and intrapleural injection. See how IT injection works in practice:

TILT Biotherapeutics technology is based on work developed at the Cancer Gene Therapy Group at the University of Helsinki.

For more information about CGTG, please see

Clinical trials
For more information about clinical trials, please see

Phase 1 trials
For more information about phase 1 trials, please see

To search for clinical trials
See e.g.

About Ovarian Cancer

About Non-Small Cell Lung Cancer

About Melanoma

About T-cell therapy

About immune checkpoint inhibitors